EU/3/19/2162
About
On 29 May 2019, orphan designation (EU/3/19/2162) was granted by the European Commission to Pharma Gateway AB, Sweden, for emixustat hydrochloride for the treatment of Stargardt’s disease.
Key facts
Active substance |
Emixustat hydrochloride
|
Disease / condition |
Treatment of Stargardt's disease
|
Date of first decision |
29/05/2019
|
Outcome |
Positive
|
EU designation number |
EU/3/19/2162
|
Sponsor's contact details
Pharma Gateway AB
Johanneslundsvägen 2
194 61 Upplands Väsby
Stockholms Lan
Sweden
E-mail: info@pharmagateway.eu
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.